These results will further enhance our chances of achieving AA in the very short term. In theory, these results should give the FDA less reason not to grant us accelerated approval. In turn, we should have a stack of potential suitors lining up to try and partner up with us based on the massive financial upside that exists with being first to market in the MSA segment.
Things are starting to really take shape and all the pieces are coming together. I have a feeling everything will start to progress a lot faster from here on in. The next 2 months I believe will be monumental....
GLTAH
Stockman
Ann: Alterity Presents Encouraging New Phase 2 Data in MSA, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $60.81K | 5.737M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 16255465 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1643984 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |